Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
about
Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.Safety of ACE inhibitor therapies in patients with chronic kidney disease.Labetalol for hypertension in pregnancy.Taking angiotensin-converting enzyme inhibitors during pregnancy: is it safe?Neonatal acute kidney injury following Valsartan exposure in utero: report of two cases.Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.Hypertension in pregnancy: natural history and treatment options.Gender Differences in Cardiovascular Drugs.Gender differences in the effects of cardiovascular drugs.Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations.Are angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers teratogenic?Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study.Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed? Reply to Lewis G and Maxwell AP [letter].
P2860
Q33571813-7739AA55-E3DC-48A4-988F-A647DD9AEF31Q34434606-9EC43FDD-F002-463E-B333-74C9C84EDB04Q35563333-5B1BE4EE-07D3-4DC2-9C0C-FA2059F58F45Q35688666-022DDB95-A7EC-409D-8EFD-3CB132B4A022Q37357631-6B154CD2-0C09-4FE5-AD4A-AD3D33DA2D96Q38027126-01BB3F3F-1811-40BC-B3D9-FEE7A62881A6Q38328807-F3C804D8-ECD2-46EA-9962-1F371E39C7E4Q38400715-2A66E98F-C0F2-4869-9F69-2974DF0DAE48Q38557955-D44EF085-8F46-4C17-AF3C-39795ABF52AAQ39193538-57718895-041E-473A-B262-15FD8FE81F34Q40437479-1222C267-ADD7-474F-BD3D-EAB83BA37CBCQ45196628-CAE1092D-DDC7-4177-A3CA-BA0F45E0CCD6Q47325847-A5EA2FDE-1D85-4962-86B2-E364D5658A77Q47823250-DC654CD4-9A0F-47F3-BDA7-761D31F9CB95
P2860
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
@en
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
@nl
type
label
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
@en
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
@nl
prefLabel
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
@en
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.
@nl
P2093
P2860
P1476
Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers
@en
P2093
P2860
P304
P356
10.3109/01443615.2011.579197
P577
2011-08-01T00:00:00Z